Kornimate/medical-research-clean huggingface dataset:
reducing hiv risk among mexican youth

Conditions: HIV Infections; AIDS; Sexually Transmitted Diseases

Summary: the broad objective of this project is to test the efficacy of a theory-based hiv risk-reduction intervention, which includes both an adolescent component and parental component, designed to reduce the adolescents' risk of sexually transmitted hiv.

sexually transmitted hiv infection among adolescents is a growing and significant problem in mexico. given the high mortality rate associated with aids, the lack of available treatment, and the social stigma associated with the disease, prevention is the key to reducing the threat of aids among this important subgroup in mexico. the study has four specific aims including 1) to determine whether the hiv risk-reduction intervention causes a greater increase in adolescents' intentions to abstain from intercourse and/or avoid unprotected intercourse at post-intervention and decreased self-reported intercourse and unprotected intercourse at 3, 6, 12, and 48 month follow-ups, compared with the general health promotion control intervention; 2) to determine whether the effects of the intervention are moderated by individual, microsystem, and macrosystem variables; 3) to identify theory-based variables that mediate effects of the hiv intervention on adolescents' self-reported behavior; and 4) to determine whether the hiv risk-reduction intervention causes a greater increase in parents' comfort with, and quantity of communication (general and hiv specific) with adolescents at post-intervention, 3, 6, 12, and 48 month follow-up compared with the general health promotion control intervention.

Eligibility criteria:
inclusion criteria: * families (adolescents \[aged 14 to 17 years of age\] and one of their parents)

Keywords: parent adolescent mexico safer sex communication randomized controlled trial hiv/aids std sexual behavior
efficacy and safety of maridebart cafraglutide in adult participants in japan who have obesity disease

Conditions: Obesity Disease

Summary: the primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * history of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise. * body mass index (bmi) ≥ 35 kg/m\^2 at screening with a current diagnosis of at least 1 of the weigh-related comorbidities specified in the japan society for the study of obesity (jasso) guideline or bmi ≥ 27 kg/m\^2 to \< 35 kg/m\^2 at screening, with a current diagnosis of at least 2 of the weight-related comorbidities specified in the jasso guideline. * for both bmi categories, at least 1 of the weight-related comorbidities must be hypertension, dyslipidemia, or t2dm. 1. hypertension: treated, or with sbp ≥ 140 mmhg, or dbp ≥ 90 mmhg at screening. 2. dyslipidemia: treated, or with ldl \> 140 mg/dl (3.6 mmol/l), or triglycerides ≥ 150 mg/dl (1.7 mmol/l), non-hdl cholesterol \> 170 mg/dl (4.4 mmol/l) or hdl \< 40 mg/dl (1.0 mmol/l) at screening. 3. t2dm: diagnosed ≥ 180 days before screening, and treated with diet and exercise alone and/or a stable treatment for at least 90 days before screening with up to 3 oral glucose-lowering medications (as per local labeling) (except for glucagon-like peptide-1 receptor agonists \[glp-1ra\] and dipeptidyl peptidase-4 \[dpp-4\] inhibitors), and have a hba1c ≥ 7% and ≤ 10% (53-86 mmol/mol) at screening. * in the opinion of the investigator, well-motivated and willing to: 1. follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice, maintain a study log(s)/diary(ies), and complete required study visits and questionnaires. 2. perform self-monitoring blood glucose (smbg) per protocol (only for participants with t2dm). exclusion criteria: * obesity induced by other endocrinological disorders or monogenetic or syndromic forms of obesity. * self-reported change in body weight \> 5 kg within 90 days before screening. * previous or planned (during the study) surgical, endoscopic, or device-based treatment for obesity. * for participants without diabetes at screening, type 1 or 2 diabetes mellitus or any other types of diabetes mellitus (except history of gestational diabetes). * for participants with t2dm at screening, any other type(s) of diabetes, mellitus except t2dm. * history of chronic pancreatitis or history of acute pancreatitis within 180 days before screening. * family (first-degree relative\[s\]) or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2). * history of unstable major depressive disorder (mdd) or other severe psychiatric disorder within 2 years before screening. * lifetime history of suicide attempt.

Keywords: overweight bmi body weight maridebart cafraglutide chronic weight management maritide type 2 diabetes mellitus t2dm
intravitreal injection site and perceived pain

Conditions: Pain

Summary: the objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.

in this pilot cross-over study, the investigators aim at exploring a factor not studied yet on the perception of pain during the injection procedure, and that is the distance of the entry site from the limbus. study population: pseudophakic patients needing multiple intravitreal injections. in case of bilateral eligibility, one eye per patient will be included (randomly- based on a random chart). intervention: two injections per eye, will be included in the study. all steps of the technique will be similar between the two injections except for the entry site distance from the limbus, which will be 3.5 in one and 4.00 mm in the other. to prevent bias, the first injection entry distance will be randomly selected (based on a randomized chart). the patient is blind to the entry distance, and a questionnaire with a visual analog pain scale will be given to the patient by a technician (to prevent any bias) to be filled after the injection. the analog pain scale is a scale of numbers from 0 to 10 representing the degree of patient's perceived pain. a score of 0 indicates no perception of pain; a score of 10 indicates a perception of the worst pain possible. the scale is also illustrated with face emojis corresponding to a written description of pain perception from no perception of pain, represented by a green, fully smiling face to perception of the worst pain possible, represented by a red, crying, fully frowning face.

Eligibility criteria:
inclusion criteria: * age 18 -100 years * diagnosis of diabetic macular edema, age related macular degeneration, or retinal vein occlusion * treated with bevacizumab, ranibizumab, aflibercept * the need for at least two intravitreal injections * pseudophakia exclusion criteria: * texas department of corrections medical records * under 18 years-of-age * first intravitreal injection experience of patient

Keywords: intravitreal injection retinal diseases age-related macular degeneration diabetic retinopathy retinal vein occlusion limbus quadrants (regions) of the eye injection site pseudophakic/aphakic eyes phakic eyes pars plana ciliary body vitrectomy crystalline lens retina bevacizumab ranibizumab aflibercept diabetic macular edema anti-vegf (vascular endothelial growth factor) vabysmo
investigating the frequency and phenotype of headaches associated with fasting during the month of ramadan.

Conditions: Headache; Migraine

Summary: headaches are more common in the month of ramadan in patients who already suffer from migraine. the object of the present study is investigate the frequency in the ramadan month .


Eligibility criteria:
inclusion criteria: * age 18-60 years. * expectation of fasting for at least 21 of 30 days during the month of ramadan. * understand and answer the questionnaire sent out in danish. exclusion criteria: * non-compliance with the headache calendar (defined as non-registration of at least 21 days per 30 days).
long-term outcome of aids-related primary central nervous system lymphoma treated with high dose methotrexate and combined antiretroviral therapy

Conditions: Central Nervous System Lymphoma; AIDS Related Lymphoma

Summary: this study aims at describing survival rates over time (kaplan-meier estimator) in patients suffering from aids-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.


Eligibility criteria:
inclusion criteria: * hiv infection * aids-related primary central nervous system lymphoma * treated with at least one infusion of methotrexate and combine antiretroviral therapy exclusion criteria: * prior non-hodgkin lymphoma
effect of acute caffeine and beetroot juice intake on strength, power, and muscular endurance

Conditions: Dietary Supplements; Caffeine; Nitrates; Sports Performance; Resistance Exercise

Summary: introduction: several studies have evaluated and confirmed the ergogenic effect of acute caffeine and beetroot juice intake on sports performance. however, there are few studies focused on the production of strength, power, and muscle endurance, particularly when both supplements are ingested together. objectives: evaluate the acute effect of combined and isolated intake of caffeine and beetroot juice on the production of strength, power, and muscle endurance in young adults, analyzing the effect of circadian rhythms (morning vs. afternoon) on the exercise performed (bench press vs. squat). methods: a total of 12 healthy and physically active participants will be recruited for the study. through a double-blind, crossover, randomized, and controlled design, participants will ingest: a) caffeine (3 mg/kg body mass); b) beetroot juice (70 ml, 6.5 mmol of nitrates); c) caffeine + beetroot juice; d) placebo (maltodextrin, 3 mg/kg). the supplements will be ingested 120 minutes (beetroot juice or placebo) and 60 minutes before (caffeine or placebo), the latter dissolved in 200 ml of water. after the ingestion period, strength, power, and muscle endurance will be analyzed with 1rm tests, strength and power tests at 25%, 50%, 75%, and 90% 1rm, and muscle endurance tests at 65% 1rm, in all cases for squat and bench press exercises. additionally, dynamometry (manual and the isometric mid-thigh pull test) and vertical jump (squat jump and countermovement jump) will be analyzed. the four experimental conditions will be conducted in the morning (8:00 am to 10:00 am) and in the afternoon (4:30 pm to 6:30 pm).


Eligibility criteria:
inclusion criteria: * age between ≥ 18 and ≤ 35 years. * body mass index (bmi) \&lt; 25 kg/m². * resistance-trained individuals (\&gt; 2 years of structured trained). * healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising. * participants must be able to perform the tests described in the following section. exclusion criteria: * history of neuromuscular diseases, heart diseases, or diseases that may affect liver or muscle metabolism. * use of drugs, other stimulants or sport supplements that interfere with the intake of the study\&#39;s dietary supplements. * sedentary habits (\&lt; 150 min/week of moderate exercise). * having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study. * performing strenuous exercise during the 48 hours prior to the tests. * failure to replicate the same food intake on the two days of the experiments. * consuming caffeine or any other stimulant after 6 pm the day before the training or tests, to avoid headaches, discomfort, or lethargy among regular caffeine consumers. * consuming foods rich in no3- (e.g., beetroot, spinach, or celery) during the 48 hours prior to each experimental condition.
using dry eye as a disease model, investigators demonstrated the optimal selection of individualized clinical interventions and the superiority of dynamic treatment discrimination in chinese medicine.

Conditions: Dry Eye Disease (DED)

Summary: in this study, dry eye disease (leukoaraiosis) is used as a model disease, and the methodological system for evaluating the clinical efficacy of chinese medicine for dry eye disease is constructed with the core of "subgrouping dynamic and static parallel group design", so as to carry out a real-world demonstration study of dry eye disease as a dominant disease in chinese medicine treatment. the purpose of this study is to demonstrate the selection of individualized clinical interventions and the superiority of dynamic diagnosis and treatment using dry eye as a disease model. the study provides a clinical example of a subgroup-based dynamic and static parallel group design for tcm clinical research on "disease-based integrated treatment". based on the conclusions of the efficacy evaluation study, investigators will provide real-world clinical data of dry eye syndrome for the artificial intelligence prediction of the integrated platform of individualized clinical evaluation and evidence support of chinese medicine with multi-source data integration.


Eligibility criteria:
inclusion criteria: * be 18-75 years of age and of any gender * meets western diagnostic criteria for dry eye * formed consent and signed the informed consent form exclusion criteria: * those who are unable to perform a dry eye examination due to various factors * patients with severe diseases of the liver or renal system, or infectious eye diseases * those who are allergic to the medications used in this study * women who are pregnant or breastfeeding mental illness or intellectual disability; participants in clinical trials of other drugs within the last 3 months.
preoperative visual aids on glaucoma surgical patients

Conditions: Anti-Glaucoma Medications

Summary: this study aims to evaluate the impact of preoperative visual aids on anxiety and pain management in patients with low educational backgrounds undergoing glaucoma filtration surgery.

a randomized, single-blinded, single-centre clinical trial was conducted at a tertiary eye hospital in shantou, china. patients scheduled for glaucoma filtration surgery were randomly assigned to either a conventional oral education group or a visual aids group. anxiety levels, pain scores, blood pressure, and pulse rates were measured at multiple time points.

Eligibility criteria:
inclusion criteria: * adult inpatients with age ≥18 years * illiterate or with ≤ 9 years of compulsory education * indications for filtering surgery exclusion criteria: * mental illness * cognitive impairment

Keywords: preoperative visit;glaucoma;filtering surgery
effect on pain and comfort associated with fistula puncture

Conditions: Hemodialysis Patients

Summary: purpose this study was carried out as the design of the targeted design in terms of targeting and comfort in the patient with hemodialysis. material and methods: it was successfully tested both in the control team of a hospital at the point of sale in turkey and with experience. by block randomization method to randomize. data were collected with "patient identification formula", "visual analog scale (vas)" and "hemodialysis comfort scale". independent sample t-test was used in the analysis of the data, analysis of variance in repeated measurements and cohen'd was used to calculate the size.

it is appropriate to suggest a non-pharmacological rather clinical rather than a literature-free method, al. also, due to the fact that the duration of anesthetic effect will expire from the dialysis treatment used (subramanian et al., 2012). participant's care continues for inappropriate pain management. this quality standard is one of the criteria of a standard rather than a preference for a simple, reliable and inexpensive non-pharmacological choice. as far as investigators know, there are very few studies investigating the effect of a patient's choice of music on pain following insertion of a needle into a fistula in hemodialysis patients. more focused on non-pharmacological types such as pharmacological and aromatherapy. therefore, the aim of this study was to examine the effect of the type of music chosen by hemodialysis patients on pain and comfort associated with fistula puncture.

Eligibility criteria:
inclusion criteria: * be volunteering, * 18 years or older, * receiving hemodialysis treatment for at least 6 months * not any hearing problem. exclusion criteria: * have hearing problem * not be volunteering.

Keywords: pain comfort
efficacy of ivmed-85 on pediatric myopia

Conditions: Myopia, Progressive

Summary: the goal of this clinical trial is to evaluate the safety and preliminary efficacy of a 1-year course of ivmed-85 eye drops for the treatment of pediatric myopia by assessing its safety effects on visual acuity and its effect on the change and/or progression of myopia. the main question\[s\] it aims to answer are: * does ivmed 85 improve visual acuity * does ivmed 85 slow or otherwise change the progression of myopia participants will use eyedrops twice a day for one year. researchers will compare ivmed 85 to a placebo.


Eligibility criteria:
inclusion criteria: * to be considered for enrollment in the study, the patient must meet all of the following criteria: 1. age 5 to 16 years and 6 months, three age groups cohorts (5-8), (9-12), and (13-16) (phase 1 patients will be exclusively age 13-16). 2. refractive error by cycloplegic refraction in both eyes: myopia -0.75 d to -9.75 d spherical equivalent; astigmatism ≤ 4.00d; anisometropia \<3.00 d 3. best corrected distance visual acuity better than or equal to snellen 20/40 (logmar equivalent 0.3) in both eyes 4. kmax \>40 d and \<50 d in both eyes 5. minimum corneal thickness \> 350 microns in both eyes 6. absence of ocular comorbidities (glaucoma, cataract, anterior segment dysgenesis, corneal scarring, juvenile rheumatoid arthritis, lens subluxation, uveitis, collagen disorders (ehlers-danlos, marfan's syndrome, osteogenesis imperfecta, retinal diseases) in both eyes 7. written informed consent from a parent or legal guardian and assent from participant 8. willing and able to comply with clinic visits and study-related procedures. exclusion criteria: a patient who meets any of the following criteria, in either eye, will be excluded from the study: 1. current or previous myopia treatment with atropine, pirenzepine, or other topical anti-muscarinic 2. significant central corneal scarring or hydrops 3. known copper allergy 4. use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of screening 5. previous cornea, glaucoma, eyelid, strabismus (exotropia or esotropia) or intraocular surgeries 6. prior history of ocular disorder (e.g., current or prior history of strabismus (exotropia or esotropia), amblyopia, glaucoma, cataract, retinal detachment or nystagmus, or abnormality of the cornea, lens, iris, ciliary body, or central retina) 7. myopic degeneration with potential visual acuity worse than snellen 20/40 (logmar equivalent 0.3) 8. intraocular pressure \>26 mmhg 9. medical conditions pre-disposing patient to degenerative myopia or abnormal ocular refractive anatomy (e.g., stickler syndrome, down syndrome, osteogenesis imperfecta, ehler's-danlos syndrome, retinopathy of prematurity) 10. participation in a clinical trial with use of any investigational drug or treatment within 30 days prior to visit 1 11. employees of the study site or their immediate families 12. pregnancy 13. hypothyroidism or hyperthyroidism 14. patient less than 17 kg weight 15. planned ophthalmic surgery during the study
rapamycin - effects on alzheimer's and cognitive health

Conditions: Mild Cognitive Impairment; Alzheimer Disease

Summary: this study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (amci) and early stage alzheimer's disease (ad).

the study will consist of a screening/baseline period of up to 90 days pre-study drug, with a 12-month (+3 day) treatment period with rapamycin, followed by a post-treatment assessment completed within 14 days of the final study drug dose, and a final assessment conducted 6-months (+14 days) after the final study drug dose. the study duration is not expected to exceed 90 weeks for participants.

Eligibility criteria:
inclusion criteria: 1. both genders and all ethnic groups 2. ages 55 to 89 years 3. diagnosis of mci or ad (mini mental status examination (mmse): 18-30; clinical dementia rating scale (cdr) = 0.5 - 1; california verbal learning test iii (cvlt-iii) delayed recall ≤16% based on age-adjusted norms, clinician approval) 4. amyloid positivity based on amyloid pet imaging 5. labs: normal blood cell counts without clinically significant excursions; normal liver and renal function; and glucose control (hba1c \< 6.5%). fasting lipid panel and prothrombin time/prothrombin time test/international normalized ration (pt/ptt/inr) within normal limits 6. a legally authorized representative (lar) designated to sign informed consent (if necessary) must attend the screening visit and accompany the participant to all remaining visits to provide reported outcomes 7. stable dose of ad medications (donepezil, rivastigmine, memantine, galantamine) for at least three months is allowed exclusion criteria: 1. diabetes (hba1c≥6.5% or antidiabetic medications) 2. history of skin ulcers or poor wound healing 3. current tobacco or illicit drug use or alcohol abuse 4. use of anti-platelet or anti-coagulant medications other than aspirin 5. current medications that affect cytochrome 450 3a4 (cyp3a4) 6. immunosuppressant therapy within the last year 7. chemotherapy or radiation treatment within the last year 8. current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities 9. untreated hypertriglyceridemia (fasting triglycerides \< 250 mg/dl) 10. current or chronic history of pulmonary disease or abnormal pulse oximetry (\<90%) 11. chronic heart failure 12. pregnancy or lactation 13. recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack 14. significant neurological conditions other than ad or mci 15. poorly controlled blood pressure (systolic bp\>160, diastolic bp\>90 mmhg - based on two readings) 16. active inflammatory, covid-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness 17. history of, or mri, or ct positive for, any space occupying lesion, including mass effect or abnormal intracranial pressure, which would indicate contraindications to lumbar puncture 18. organ transplant recipients

Keywords: cognition alzheimer's disease biomarkers neuroimaging
neotrofin for treatment of chemotherapy-induced peripheral neuropathy

Conditions: Peripheral Nervous System Diseases; Chemotherapy-Induced Peripheral Neuropathy

Summary: this study will assess the safety and efficacy of neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.


Eligibility criteria:
* patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy. * sensory or motor neuropathy must be \>/= grade 2 per common toxicity criteria at baseline. * in patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable. * patient must have normal hematological cell counts. * patient must have a life expectancy of \>/= 3 months.